Adverum Biotechnologies announced the initiation of the phase 2 INFINITY trial to assess a single intravitreal injection of ADVM-022 in patients with diabetic macular edema.
The multicenter, randomized, double-masked, active comparator-controlled trial will enroll approximately 33 patients. Researchers will evaluate the time to worsening of DME disease activity in patients who receive an intravitreal injection of ADVM-022 (AAV.7m8-aflibercept) compared with a single aflibercept injection, according to a press release.
The INFINITY trial will include three arms. Arm 1 will receive a higher dose
Uncategorized